The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Official Title: A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease
Study ID: NCT00374296
Brief Summary: In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Veterans Affairs Medical Center, Kansas City, Missouri, United States
University of Rochester Medical Center, Rochester, New York, United States
Gabrail Cancer Center, Canton, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Ohio State University Medical Center - James Cancer Hospital, Columbus, Ohio, United States
MD Anderson Cancer Center, Houston, Texas, United States
Hamilton Health Sciences - McMaster Hospital, Hamilton, Ontario, Canada
UHN - Princess Margaret Hospital, Toronto, Ontario, Canada
Hopital Charles Lemoyne, Greenfield Park, Quebec, Canada
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada
Sir Mortimer Davis-Jewish General Hospital, Montreal, Quebec, Canada
Universite de Sherbrooke, Service d'hematologie, Sherbrooke, Quebec, Canada
Name: Gregory Reid, MSc, MBA
Affiliation: MethylGene Inc.
Role: STUDY_DIRECTOR